Biotech News

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

BioXcel (BTAI)BioXcel2026-05-28 11:00 ESTClinical readout

NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY

Open original release

Related news

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

KYMRKymera2026-05-05 11:00 EST

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

ELVNEnliven Therapeutics2026-05-12 13:53 EST

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

ELVNEnliven Therapeutics2026-06-03 20:05 EST

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

IMTXImmatics2026-05-30 12:00 EST

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

DNLIDenali Therapeutics2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

IMTXImmatics2026-05-31 13:00 EST

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

View all latest news

BioXcel

BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.

Recent company news

BTAIBioXcel2026-05-28 11:00 EST

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

BTAIBioXcel2026-04-17 11:00 EST

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

BTAIBioXcel2026-04-08 11:00 EST

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

BTAIBioXcel2026-04-01 11:00 EST

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

Stock data

Close: 0.87 USD
Market cap: 36.74M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States